Quantisnow Logo
Dashboard

Amendment: Director Bilkie Robert M disposed of 1,764 shares, acquired 1,764 shares and bought $5,574 worth of shares (600 units at $9.29) (SEC Form 4)

$GRF
Finance/Investors Services
Finance
Get the next $GRF alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $GRF alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRF

DatePrice TargetRatingAnalyst
More analyst ratings

$GRF
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

    The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024, and the payment date is December 19, 2024. On a preliminary basis, this distribution represents a combination of net investment income of $0.0754 per share, and long-term capital gains of $0.6046 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. The Fund is a closed-end investment compan

    $GRF
    Finance/Investors Services
    Finance

  • Eagle Capital Growth Fund Declares Year-End Distribution of $0.35 Per Share in Cash

    The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.35 per share in cash. The record date for this distribution is November 24, 2023, and the payment date is December 15, 2023. On a preliminary basis, this distribution represents a combination of net investment income of $0.07 per share, short-term capital gains of $0.03 per share, and long-term capital gains of $0.25 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. T

    $GRF
    Finance/Investors Services
    Finance

  • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRF
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GRF
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GRF
 SEC Filings

See more

$GRF
 Leadership Updates

Live Leadership Updates

See more

  • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRF
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more